- Home
- DXR vs INKT Comparison
DXR vs INKT Comparison
Compare DXR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | INKT |
|---|---|---|
| Founded | 1970 | 2017 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 59.4M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXR | INKT |
|---|---|---|
| Price | $10.27 | $11.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 5.6K | ★ 6.3K |
| Earning Date | 02-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $8.48 |
| 52 Week High | $14.76 | $16.80 |
Technical Indicators
Market Signals| Indicator | DXR | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 50.04 |
| Support Level | $9.38 | $10.79 |
| Resistance Level | $12.08 | $12.20 |
| Average True Range (ATR) | 0.40 | 0.66 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 31.17 | 34.86 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.